Allarity Therapeutics, Inc.
ALLR Nasdaq
SEC CIK 1860657
Follow Allarity Therapeutics
Weekly email: filings, results
Revenue, last quarter
$5K
Net income
−$6.2M
−121% vs same quarter last year
EPS, diluted
−$0.39
−105.3% vs same quarter last year
Operating cash flow
−$2.9M
+15.6% vs same quarter last year
Source: SEC XBRL filings · latest filing
Show the numbers
| Year | Net income |
|---|---|
| FY25 | −$11.2M |
| FY24 | −$24.5M |
| FY23 | −$11.9M |
| FY22 | −$16.1M |
| FY21 | −$26.6M |
| FY20 | −$6.6M |
| FY19 | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$14.8M |
| FY24 | −$17.7M |
| FY23 | −$12.7M |
| FY22 | −$16.8M |
| FY21 | - |
| FY20 | −$7.3M |
| FY19 | - |